Immatics (IMTX) Surges 7.5%: Is This an Indication of Further Gains?Zacks Investment Research • 06/19/23
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAMEGlobeNewsWire • 05/02/23
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic CollaborationGlobeNewsWire • 05/01/23
Does Immatics (IMTX) Have the Potential to Rally 77% as Wall Street Analysts Expect?Zacks Investment Research • 10/31/22
Wall Street Analysts See an 81% Upside in Immatics (IMTX): Can the Stock Really Move This High?Zacks Investment Research • 10/14/22
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAMEGlobeNewsWire • 10/10/22
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022GlobeNewsWire • 09/10/22
Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAMEGlobeNewsWire • 08/23/22
Wall Street Analysts Think Immatics (IMTX) Could Surge 82%: Read This Before Placing a BetZacks Investment Research • 08/12/22
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?Zacks Investment Research • 07/20/22